Oncobit

Oncobit develops next-generation cancer diagnostics and monitoring technologies that enable personalized cancer care through high-precision, cutting-edge monitoring solutions based on simple blood samples. The company uses state-of-the-art technologies to develop cancer-specific monitoring tests that provide physicians with optimal therapy-decision support, offering innovative and robust solutions to closely, precisely, and reliably monitor cancer and treatment response. Oncobit's product portfolio includes OncobitDx for precise diagnosis, OncobitLB for monitoring, and OncobitPM for identification of cancer recurrence. The CE-IVDR-marked digital PCR solution tracks circulating tumor DNA (ctDNA) dynamics, enabling real-time quantitative assessment from a simple blood draw. Oncobit has launched Oncular in the U.S. market through a partnership with TrilliumBiO, bringing its uveal melanoma monitoring solution to physicians across the U.S. through TrilliumBiO's multi-accredited laboratory. The company is engaged in a joint EADO-EUMelaReg ctDNA project aimed at integrating ctDNA into routine melanoma follow-up, evaluating clinical utility to detect relapse and complement established monitoring approaches. Clinical partners include University Hospital Zurich, University Medical Center Hamburg-Eppendorf, and University Hospital Heidelberg. Founded in 2018 and headquartered in Zurich, Switzerland, Oncobit has raised $6.6M in Series A funding from investors including AVANTECA, GF Group Holding, Swiss ICT Investor Club, and HEMEX.